secwatch / observer

8-K filed Jun 02, 2025 23:59 UTC CIK 0001293971

m_and_a confidence high sentiment positive materiality 1.00

Carlyle and SK Capital complete acquisition of bluebird bio; stock delisted, new CEO David Meek

bluebird bio, Inc.

Acquisition closed June 2, 2025; shareholders could elect $3.00 + one CVR per share, or $5.00 all-cash per share.
Approximately 59.8% of outstanding shares validly tendered before expiration; all conditions satisfied.
David Meek appointed CEO; prior CEO Andrew Obenshain and other executives terminated, eligible for severance.
Stock halted and delisted from Nasdaq; company will file Form 15 to terminate registration.
Carlyle and SK Capital provide primary capital to support scaled access to gene therapies for sickle cell, β-thalassemia, and CALD.

item 1.01item 2.01item 3.01item 3.03item 5.01item 5.02item 5.03item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Najoh Tita-Reid

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Andrew Obenshain

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Mark Vachon

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Richard Paulson

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Joseph Vittiglio

Other Named Officer

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.

Departed

Charlotte Jones-Burton

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

John O. Agwunobi

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Nick Leschly

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Andrew Obenshain

Other Named Officer

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.

Departed

Mike Cloonan

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

Lis Leiderman

Director

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

each of Mark Vachon, John O. Agwunobi, M.D., Mike Cloonan, Charlotte Jones-Burton, M.D., Lis Leiderman, M.D., Nick Leschly, Andrew Obenshain, Richard Paulson and Najoh Tita-Reid ceased to be members of the Board and ceased to be members of any committees of the Board on which such directors served, effective as of the Effective Time.

Departed

O. James Sterling

Other Named Officer

bluebird bio, Inc.

Effective: 2025-06-02
Filed: Jun 02, 2025 23:59 UTC

the employment of each of Messrs. Andrew Obenshain, Joseph Vittiglio, and O. James Sterling (the “Executives”) has terminated as of the Effective Time.

Source: SEC EDGAR

accession 0001193125-25-132850

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.